Emergent BioSolutions (EBS) 10-Q2017 Q2 Quarterly report

Filed: 4 Aug 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: answer, antitrust, Bayview, BESP, broker, clearance, deliverable, denied, elicit, eligible, Genome, GSK, heard, inactivated, infection, Japanese, lease, linked, Live, methodology, model, optimize, Pasteur, policy, publicly, quote, Sanofi, satisfaction, SE, tied, unethical, upfront, Valneva, waiting, ZIKV

Removed: accrued, assessment, decision, discrete, exercising, exposed, intentionally, natural, notified, pandemic, prepaid, PreviThrax, prioritization, rarely, rPA, statistically, varied, volume

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

EBS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 12

	Ratio of Earnings to Fixed Charges
	Year to Date
	June 30,		Year Ended December 31,
(in thousands)	2017		2016		2015		2014		2013		2012

Pretax income from continuing operations (1)	$	20,366	$	99,221	$	135,716	$	84,194	$	83,439	$	68,011

Fixed charges
Interest expense		3,814		8,270		7,834		7,480		1,973		2,177
Debt issuance cost		763		1,526		1,564		3,290		319		67
Total fixed charges (2)		4,577		9,796		9,398		10,770		2,292		2,244

Noncontrolling interest in pretax income (3)		-		-		-		-		876		5,381
Capitalized interest (4)		834		2,179		2,875		2,530		1,973		2,177

Earnings ((1) + (2) -(3) -(4))		24,109		106,838		142,239		92,434		82,882		62,697
Fixed charges		4,577		9,796		9,398		10,770		2,292		2,244

Ratio of earnings to fixed charges		5.3		10.9		15.1		8.6		36.2		27.9

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.